Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Eric Raymond, Timothy Hobday, Daniel Castellano, Diane Reidy-Lagunes, Rocío García-Carbonero, Alfredo Carrato

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement in progression-free survival in patients with unresectable, advanced, or metastatic GEP-NETs. Based on this finding, sunitinib became the first targeted drug approved for the treatment of GEP-NETs, paving the way for the approval of other anticancer agents in this drug-orphan disease. To date, results of trials involving other multitargeted tyrosine kinase inhibitors, such as sorafenib, the monoclonal antibody bevacizumab, and insulin-like growth factor 1 receptor inhibitors, have also shown promising results, and some are already being studied in phase III trials. This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs.

Original languageEnglish (US)
Pages (from-to)S19-S26
JournalCancer and Metastasis Reviews
Issue numberSUPPL. 1
StatePublished - Mar 2011


  • Angiogenesis
  • Bevacizumab
  • Carcinoid tumors
  • IGF-1R
  • Orphan disease
  • Pancreatic neuroendocrine tumors
  • Sorafenib
  • Sunitinib
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this